β-Lactams against the Fortress of the Gram-Positive Staphylococcus aureus Bacterium

JF Fisher, S Mobashery - Chemical reviews, 2020 - ACS Publications
The biological diversity of the unicellular bacteria—whether assessed by shape, food,
metabolism, or ecological niche—surely rivals (if not exceeds) that of the multicellular …

Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet …

M Gatti, M Andreoni, F Pea, P Viale - Drug Design, Development …, 2021 - Taylor & Francis
Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-
life coupled with excellent in vitro activity against multidrug-resistant Gram-positives …

Bacteriophage therapeutics: a primer for clinicians on phage‐antibiotic combinations

T Morrisette, R Kebriaei, KL Lev… - … : The Journal of …, 2020 - Wiley Online Library
Multidrug‐resistant organisms have caused a marked depletion of effective antimicrobials,
and the narrow pipeline of antibiotics has demanded the need to find novel therapeutic …

Anti-biofilm approach in infective endocarditis exposes new treatment strategies for improved outcome

CJ Lerche, F Schwartz, M Theut, EL Fosbøl… - Frontiers in Cell and …, 2021 - frontiersin.org
Infective endocarditis (IE) is a life-threatening infective disease with increasing incidence
worldwide. From early on, in the antibiotic era, it was recognized that high-dose and long …

Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination

R Kebriaei, KL Lev, RM Shah, KC Stamper… - Microbiology …, 2022 - Am Soc Microbiol
Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on
tissues and medical devices. Phage+ antibiotic combinations (PAC) may be more active on …

Bacteriophage‐antibiotic combination therapy for multidrug‐resistant Pseudomonas aeruginosa: In vitro synergy testing

DJ Holger, KL Lev, R Kebriaei… - Journal of Applied …, 2022 - academic.oup.com
Aims Here, we investigate the impact of phage‐antibiotic combinations (PAC) on bacterial
killing, resistance development and outer membrane vesicle (OMV) production in multidrug …

Bacteriophage-antibiotic combination strategy: an alternative against methicillin-resistant phenotypes of Staphylococcus aureus

R Kebriaei, K Lev, T Morrisette… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Comparative time-kill experiments with Staphylococcus aureus bacteriophage (phage) Sb-1
alone and phage-antibiotic combinations (PACs) against two methicillin-resistant S. aureus …

[HTML][HTML] Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus

BJ Werth, NK Ashford, K Penewit, A Waalkes… - Clinical Microbiology …, 2021 - Elsevier
Objectives Dalbavancin is a lipoglycopeptide active against methicillin-resistant
Staphylococcus aureus (MRSA). Its long half-life (8.5–16 days) allows for once-weekly or …

The evolving reduction of vancomycin and daptomycin susceptibility in MRSA—salvaging the gold standards with combination therapy

T Morrisette, S Alosaimy, JC Abdul-Mutakabbir… - Antibiotics, 2020 - mdpi.com
Methicillin-resistant Staphylococcus aureus (MRSA) is associated with substantial morbidity
and mortality. Vancomycin (VAN) has been used as the gold standard treatment for invasive …

Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin

A Oliva, S Carbonara, V Cianci, M Crapis… - Expert Review of Anti …, 2023 - Taylor & Francis
ABSTRACT Introduction Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) are a
common reason of Emergency Department (ED) access and account for a considerable …